Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

By I. Stratton, A. Adler, A. Neil, D. Matthews, S. Manley, C. Cull, D. Hadden, R. Turner, Rury R. Holman. British medical journal, 2000

9,134 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/b159a09c94953a1686bc1e8216973ead22de7e41

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. Ralph DeFronzo
2. Nur Samsu

In Endocrinology, Diabetes and Metabolism

1. V. Basevi
2. Ralph DeFronzo
3. K. ‐. Tseng
4. M. Levine
5. John B. Buse
6. D. Nathan
7. E. Ferrannini
8. Guanghong Jia

Citations in the corpus

• Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. (2015, positive): “The UKPDS studied the incidence of macrovascular or macrovascular complications in a population of 5102 patients with newly diagnosed type 2 diabetes in 23 centers in the United Kingdom between 1977 and 1991 [65 – 67].”
• Standards of Medical Care in Diabetes—2012 (2011, background): “In these trials, treatment regimens that reduced average A1C to 7% ( 1% above the upper limits of normal) were associated with fewer longterm microvascular complications; however, intensive control was found to increase the risk of severe hypoglycemia and weight gain (26,27).”
• Collaborative Care for Patients with Depression and Chronic Illnesses (2010, neutral): “Oral hypoglycemic agents 34 (38) 23 (25) 0.”
• Mechanisms of diabetic complications. (2013, background): “Although there is convincing evidence that optimizing glycemic control by targeting a number of sites (FIGURE 2) is the most effective therapeutic strategy in the clinical management of microvascular complications of diabetes (204, 531, 560), the recent ADVANCE (454) and ACCORD (203) studies have sh”
• Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association (2014, background): “A1C reflects average glycemia over 2–3 months (57) and strongly predicts diabetes complications (43,61).”
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012, background): “Relationship of glycemic control to outcomes It is well established that the risk of microvascular and macrovascular complications is related to glycemia, as measured by HbA1c; this remains a major focus of therapy (29).”
• Standards of Medical Care in Diabetes–2006 (2006, background): “In these trials, treatment regimens that reduced average A1C to 7% ( 1% above the upper limits of normal) were associated with fewer longterm microvascular complications; however, intensive control was found to increase the risk of severe hypoglycemia and weight gain (29,30).”